Sep 12, 2019 – Announcement:
Crestone, Inc. Secures NIH Funding for Phase 2 Clinical Trial of Novel Antibiotic Candidate, CRS3123 to Treat C. difficile infection.
Learn More:
NIH Funding Secured for Phase 2 Clinical Trial of CRS3123
Become a Part of Our Projects
Interested in helping further our research into novel antibacterial agents? We’d be thrilled to have your help, either as an investor, a team member, or a participant in our ongoing clinical studies.
Inquiries
Have a question or comment? Follow the link below to contact us about general inquiries.
Careers
Find work in a team-oriented environment at one of the leading Colorado pharma companies.
Investors
If you're interested in becoming an investor to help fund our research and development, contact us today.